The BEND3 Knockout HEK293T Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function studies of the BEN domain-containing transcriptional repressor BEND3. This product consists of a heterogeneous pool of HEK293T cells carrying targeted disruptions at the BEND3 genomic locus, enabling researchers to investigate the consequences of BEND3 ablation in a well-characterized human embryonic kidney epithelial background. The polyclonal format avoids clonal selection artifacts, providing a robust model for population-level analyses of gene silencing, chromatin remodeling, and heterochromatin maintenance.
HEK293T cells are an immortalized human embryonic kidney line stably expressing the SV40 large T antigen, which enhances episomal plasmid replication and boosts protein expression yields. This host cell line is widely employed for transient protein production, viral packaging, and signaling assays due to its high transfectability and rapid growth. The epithelial origin and stable karyotype make HEK293T a versatile platform for examining epigenetic regulators like BEND3, whose functions intersect with cell cycle control and chromatin organization. The knockout is achieved through CRISPR/Cas9-mediated gene disruption, generating a heterogeneous pool that reflects the natural diversity of editing outcomes while maintaining the core genetic background of the parental line.
BEND3 acts as a sequence-specific transcriptional repressor by recognizing DNA motifs through its tandem BEN domains, subsequently recruiting the nucleosome remodeling and deacetylase (NuRD) complex and heterochromatin protein 1 (HP1) factors. Direct interaction partners include HDAC1, MTA1, RBBP4, and the HP1 homologs CBX1, CBX3, and CBX5, leading to histone deacetylation, chromatin compaction, and stable gene silencing. Key downstream targets subject to BEND3-mediated repression encompass CDKN1A (p21), ribosomal RNA genes (rDNA), and MYC, placing BEND3 at the nexus of proliferation control and ribosome biogenesis. BEND3 activity is modulated by upstream signals such as the SP1 transcription factor, DNA methylation patterns, and SUMO conjugation machinery, which collectively tune its repressive potency on chromatin.
In the HEK293T context, BEND3 knockout disrupts native transcriptional networks that govern heterochromatin maintenance and cell cycle progression. Although HEK293T cells are widely used for recombinant expression, their endogenous epigenetic machinery remains highly functional, making them a suitable model for interrogating BEND3-dependent gene silencing mechanisms relevant to cancer biology, particularly acute myeloid leukemia where BEND3 dysregulation has been implicated. Loss of BEND3 function in this system permits direct assessment of NuRD complex dynamics, HP1 redistribution, and derepression of growth-suppressive or ribosomal loci, offering insights into the molecular underpinnings of malignant transformation and epigenetic therapy targets.
This knockout model facilitates a wide spectrum of experimental applications, including chromatin immunoprecipitation (ChIP-qPCR) to map BEND3 binding sites and associated histone modifications, co-immunoprecipitation to dissect NuRD complex integrity, and RNA-seq to define global transcriptomic changes upon BEND3 loss. Quantitative RT-PCR and Western blotting enable validation of downstream targets such as CDKN1A and MYC, while immunofluorescence visualizes alterations in heterochromatin foci (HP1 localization). Functional assays like cell proliferation, apoptosis, and reporter gene analyses directly link BEND3 activity to phenotypic outcomes, and the polyclonal pool is compatible with high-throughput small-molecule screening for epigenetic modulators. For further details or technical inquiries about this product, please contact Ascent Research.
